Biopharmaceutical Third-party Logistics Market (2026 - 2033)

Biopharmaceutical Third-Party Logistics Market Summary

The global biopharmaceutical third-party logistics market size was valued at USD 152.0 billion in 2025 and is projected to grow from USD 161.4 billion in 2026 to USD 258.4 billion by 2033, at a CAGR of 6.9% from 2026 to 2033. North America dominated the market, accounting for the largest share of 41.7% in 2025. The biopharmaceutical third-party logistics (3PL) industry is experiencing robust growth, driven by the expanding commercialization of biologics and biosimilars, increasing demand for temperature-controlled and GDP-compliant logistics infrastructure, rising outsourcing of supply chain operations by pharmaceutical and biotechnology companies, growth in clinical trials and advanced therapies including cell and gene therapies, and continuous investments in digital supply chain technologies for end-to-end product visibility and regulatory compliance.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The increasing complexity of global biopharmaceutical distribution, combined with stringent handling requirements for temperature-sensitive products and growing cross-border pharmaceutical trade, is encouraging manufacturers to partner with specialized third-party logistics providers offering integrated transportation, warehousing, packaging, inventory management, and cold chain capabilities.

The rapid expansion of biologics, biosimilars, and advanced therapies remains one of the primary factors driving market growth. Unlike conventional pharmaceuticals, biologics require specialized transportation, temperature-controlled storage, validated packaging, and continuous monitoring throughout the supply chain to preserve product efficacy and regulatory compliance. The growing commercialization of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies has significantly increased the demand for specialized logistics providers with GDP-certified infrastructure and global distribution networks.

To learn more about this report, Download Free Sample Report

Furthermore, increasing outsourcing of pharmaceutical supply chain operations is another major driver supporting market expansion. Pharmaceutical and biotechnology companies are increasingly relying on specialized third-party logistics providers to optimize distribution efficiency, improve regulatory compliance, reduce operational costs, and enhance supply chain resilience across global markets. Managing highly regulated biopharmaceutical supply chains requires specialized expertise in cold chain management, customs clearance, serialization, inventory control, and last-mile delivery, making outsourcing a cost-effective and scalable solution. Strategic investments and acquisitions across the logistics industry further demonstrate this trend. For instance, in March 2025, DHL announced the acquisition of specialty pharmaceutical logistics provider CryoPDP to strengthen its capabilities in clinical trial logistics, biopharma distribution, and cell and gene therapy transportation, further expanding its integrated healthcare logistics portfolio and specialized cold chain network.

However, the market growth is constrained by the high capital investment required for temperature-controlled infrastructure, stringent global regulatory compliance requirements, and the operational complexity associated with transporting highly sensitive biopharmaceutical products across international markets. Nevertheless, increasing commercialization of advanced therapies, expanding biologics pipelines, growing adoption of digital supply chain technologies, and continued investments in GDP-compliant cold chain infrastructure are expected to create substantial long-term opportunities for biopharmaceutical third-party logistics providers. The market is expected to maintain steady growth as pharmaceutical manufacturers increasingly outsource complex logistics operations to specialized partners capable of delivering secure, compliant, and globally integrated supply chain solutions.

Market Dynamics

Market Concentration & Characteristics

The biopharmaceutical third-party logistics market growth stage is medium, and the pace of growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.

Innovation remains a critical competitive factor in the biopharmaceutical third-party logistics industry, with logistics providers investing in advanced cold chain technologies, Internet of Things-based monitoring systems, artificial intelligence-driven supply chain analytics, warehouse automation, and digital visibility platforms. The growing distribution of biologics, biosimilars, vaccines, and advanced therapies is driving the adoption of technologies that enhance shipment monitoring, inventory accuracy, regulatory compliance, and product integrity. The continued advancement of intelligent logistics solutions enables service providers to improve operational efficiency, reduce distribution risks, strengthen traceability, and support the growing demand for specialized healthcare logistics services.

To learn more about this report, Download Free Sample Report

Mergers and acquisitions continue to influence the biopharmaceutical 3PL market by expanding healthcare logistics networks, strengthening cold chain capabilities, and broadening integrated supply chain service offerings. Strategic acquisitions enable logistics providers to enhance expertise in temperature-controlled transportation, clinical trial logistics, warehousing, packaging, customs management, and last mile distribution while extending their global operational footprint. The transactions further improve service capacity, strengthen customer relationships, and increase access to high-growth pharmaceutical markets across major regions.

Regulatory compliance remains a major factor shaping the biopharmaceutical 3PL industry. Logistics providers are required to comply with Good Distribution Practice guidelines, product serialization requirements, temperature-monitoring standards, quality management systems, and import and export regulations established by health authorities in different countries. The increasing focus on product traceability, validated transportation processes, documentation accuracy, and quality assurance increases operational complexity while creating competitive advantages for providers with established regulatory expertise and globally compliant logistics infrastructure.

The biopharmaceutical third-party logistics providers are expanding their service portfolios to deliver integrated supply chain solutions across the pharmaceutical distribution lifecycle. Many providers now offer temperature-controlled transportation, warehousing, inventory management, packaging, labeling, customs brokerage, clinical trial logistics, direct-to-patient delivery, and digital shipment monitoring through a single platform. The integrated service approach improves operational efficiency, simplifies supply chain management, and enables pharmaceutical and biotechnology companies to optimize global distribution activities while maintaining regulatory compliance.

Regional expansion continues to strengthen the global presence of biopharmaceutical third-party logistics providers. Companies are establishing new GDP-compliant distribution centers, temperature-controlled warehouses, and healthcare logistics hubs across North America, Europe, Asia Pacific, Latin America, and the Middle East to address the increasing demand for biologics and specialty pharmaceuticals. The geographic expansion improves supply chain flexibility, strengthens regional distribution capabilities, supports local regulatory compliance, and enables logistics providers to deliver faster and more reliable pharmaceutical distribution services across global markets.

Impact of U.S. Tariffs on the Global Biopharmaceutical Third-Party Logistics (3PL) Market

The imposition of U.S. tariffs on imported pharmaceutical packaging materials, refrigeration equipment, monitoring devices, transportation components, and specialized logistics infrastructure has increased capital and operating costs across the biopharmaceutical 3PL industry. Higher prices for cold storage systems, insulated packaging, temperature monitoring equipment, and transportation assets have elevated investment requirements for logistics providers expanding healthcare distribution networks. In addition, tariffs on certain imported materials and equipment have contributed to procurement delays and supply chain disruptions, affecting infrastructure deployment and operational efficiency.

Pharmaceutical and biotechnology companies may face higher logistics costs for the transportation and storage of biologics, vaccines, and advanced therapies that require specialized cold chain handling. In response, many logistics providers have diversified supplier networks, increased regional sourcing of equipment and consumables, and strengthened inventory management practices to improve supply continuity. Investments in domestic cold chain infrastructure, regional distribution centers, and digital supply chain technologies are also helping to mitigate tariff-related cost pressures.

Demand for specialized biopharmaceutical logistics services remains strong, supported by the continued expansion of biologics pipelines, increasing commercialization of advanced therapies, and growing outsourcing of pharmaceutical supply chain operations. Long-term logistics contracts, strategic infrastructure investments, and the development of localized healthcare distribution networks are expected to partially offset the impact of higher input costs. Consequently, the expansion of regional cold chain hubs, digital visibility platforms, and GDP-compliant logistics infrastructure is likely to improve supply chain resilience while supporting sustained growth in the global biopharmaceutical third-party logistics market.

Analyst Perspective

The biopharmaceutical third party logistics market is experiencing steady growth, driven by the increasing commercialization of biologics, biosimilars, vaccines, and advanced therapies, along with rising outsourcing of pharmaceutical supply chain operations. Growing demand for temperature-controlled transportation, GDP-compliant warehousing, inventory management, packaging, customs management, and integrated distribution services is speeding up the adoption of specialized logistics providers with advanced cold chain infrastructure and digital supply chain capabilities. Furthermore, the companies with integrated logistics solutions, regulatory expertise, advanced digital capabilities, and extensive global distribution networks are expected to strengthen their competitive position and support market growth over the forecast period.

Technological Advancements

To learn more about this report, Download Free Sample Report

Technological innovation continues to reshape the biopharmaceutical third-party logistics market by improving supply chain visibility, operational efficiency, regulatory compliance, and product integrity across global distribution networks. The growing adoption of digital monitoring systems, intelligent analytics, automated warehousing, blockchain-enabled traceability, and advanced temperature-controlled packaging is enabling logistics providers to manage increasingly complex biopharmaceutical supply chains with greater precision and reliability. These technologies support continuous monitoring of high-value pharmaceutical products, strengthen quality assurance processes, and improve responsiveness to operational disruptions while facilitating compliance with evolving global regulatory requirements. Digital transformation is also enhancing inventory optimization, transportation planning, and end-to-end shipment visibility, enabling pharmaceutical manufacturers to reduce distribution risks and improve supply chain performance. At the same time, warehouse automation and advanced cold chain technologies are increasing operational scalability and supporting the safe handling of biologics, biosimilars, vaccines, and advanced therapies with stringent temperature requirements.

As pharmaceutical companies continue expanding global commercialization activities and outsourcing logistics operations, investments in next-generation digital infrastructure and smart logistics technologies are expected to remain a key competitive differentiator. Continued technological modernization across transportation, warehousing, packaging, and supply chain management is anticipated to strengthen service capabilities, improve distribution resilience, and support the long-term expansion of the global biopharmaceutical third-party logistics industry.

Pricing Model Analysis

The pricing structure in the biopharmaceutical 3PL market is primarily determined by the scope of outsourced services, operational complexity, shipment volumes, regulatory requirements, and contract duration. The fee for service model remains suitable for customers requiring individual logistics services with flexible engagement terms, while project-based pricing addresses short-term commercial and clinical distribution requirements. The full-time equivalent model supports organizations that require dedicated logistics personnel for ongoing operational activities, particularly during large-scale commercialization and supply chain expansion programs. The long-term dedicated contract model continues to account for a considerable share of outsourcing agreements as pharmaceutical manufacturers increasingly consolidate multiple logistics functions under strategic partnerships.

To learn more about this report, Download Free Sample Report

The increasing distribution of biologics, biosimilars, vaccines, and advanced therapies is encouraging logistics providers to offer flexible commercial structures that align with varying customer requirements across clinical and commercial supply chains. The continued expansion of global pharmaceutical outsourcing, increasing regulatory complexity, and growing demand for integrated cold chain solutions are expected to support the adoption of multiple pricing models across the biopharmaceutical 3PL industry over the forecast period.

Supply Chain Insights

The non-cold chain logistics segment led the market with the largest revenue share of 78.5% in 2025. The segment growth is attributed to the large volume of conventional pharmaceuticals, over-the-counter medicines, oral solid dosage forms, and medical products that do not require temperature-controlled transportation or storage. These products account for a significant share of global pharmaceutical distribution and are transported through established logistics networks with lower operating costs than cold chain services. The increasing production of generic medicines, the expansion of pharmaceutical manufacturing, and the rising international trade in non-temperature-sensitive products continue to support demand for non-cold-chain biopharmaceutical logistics services.

The cold chain logistics segment is expected to grow at the fastest CAGR during the forecast period. The growth is driven by the increasing commercialization of biologics, biosimilars, vaccines, cell and gene therapies, and other temperature-sensitive pharmaceuticals requiring specialized storage and transportation conditions. Pharmaceutical manufacturers are increasingly outsourcing cold chain logistics to specialized providers offering GDP-compliant infrastructure, real-time temperature monitoring, validated packaging, and integrated distribution services. Furthermore, expanding biologics pipelines, increasing global vaccine distribution, and growing investment in advanced healthcare logistics infrastructure are expected to further support the growth of the cold chain logistics segment over the forecast period.

Service Type Insights

The warehousing and storage segment led the biopharmaceutical third-party logistics market with the largest revenue share of 43.1% in 2025. The growth of this segment is attributed to the increasing demand for GDP-compliant storage facilities for biologics, biosimilars, vaccines, and specialty pharmaceuticals across global supply chains. Pharmaceutical manufacturers increasingly outsource warehousing operations to specialized logistics providers offering temperature-controlled storage, inventory management, order fulfillment, and quality-controlled handling. The expansion of pharmaceutical manufacturing, increasing commercialization of high-value therapies, and growing need for regional distribution centers to support global product availability continue to strengthen demand for specialized biopharmaceutical warehousing and storage services.

To learn more about this report, Download Free Sample Report

The transportation segment is projected to grow at the second-fastest CAGR during the forecast period. The growth is driven by the increasing global distribution of biologics, specialty pharmaceuticals, and advanced therapies that require secure and compliant transportation solutions. Pharmaceutical companies are expanding international distribution networks while increasing outsourcing of transportation activities to specialized logistics providers with expertise in cold chain management, real-time shipment monitoring, and regulatory compliant distribution. Furthermore, rising cross-border pharmaceutical trade, growing demand for faster product delivery, and continued investments in temperature-controlled transportation infrastructure are expected to support the sustained growth of the transportation segment over the forecast period.

Regional Insights

North America dominated the biopharmaceutical third-party logistics market with the largest revenue share of 41.7% in 2025. The market is experiencing significant growth, supported by a well-established pharmaceutical and biotechnology industry, the increasing commercialization of biologics and specialty pharmaceuticals, and advanced healthcare logistics infrastructure. The growing demand for temperature-controlled transportation, GDP-compliant warehousing, and integrated supply chain solutions is encouraging pharmaceutical manufacturers to expand outsourcing activities. The region benefits from strong investments in cold chain infrastructure, digital logistics technologies, and healthcare distribution networks. Continued growth in biologics production, clinical research activities, and advanced therapy commercialization is expected to support market expansion over the forecast period.

To learn more about this report, Download Free Sample Report

U.S. Biopharmaceutical Third-party Logistics Market Trends

The U.S. biopharmaceutical third-party logistics industry is expected to grow significantly over the forecast period. The market growth is supported by the country's large pharmaceutical manufacturing base, increasing biologics production, and rising demand for specialized cold chain logistics services. The growing number of cell and gene therapies, expanding clinical trial activities, and increasing outsourcing of healthcare supply chain operations are contributing to demand for integrated logistics solutions. In addition, investments in automated distribution centers, digital supply chain technologies, and temperature-controlled transportation networks are expected to support continued market growth.

The Canada biopharmaceutical third-party logistics market is expected to grow at a significant CAGR during the forecast period.The market is anticipated to witness steady growth owing to increasing pharmaceutical manufacturing activities, expanding biologics distribution, and continued investment in healthcare infrastructure. The rising demand for temperature-controlled logistics, regulatory compliant warehousing, and efficient cross-border distribution is encouraging pharmaceutical companies to strengthen outsourcing partnerships. Furthermore, increasing clinical research activities and government support for life sciences are expected to contribute to market expansion.

Europe Biopharmaceutical Third-party Logistics Market Trends

The European biopharmaceutical third-party logistics industry is experiencing steady growth, supported by a mature pharmaceutical industry, increasing biologics production, and stringent Good Distribution Practice requirements. The growing commercialization of biosimilars, vaccines, and advanced therapies is increasing demand for specialized cold chain logistics and integrated distribution services. The region benefits from an established healthcare logistics network, advanced transportation infrastructure, and the presence of leading pharmaceutical manufacturers. Continued investments in GDP-compliant warehousing and regional distribution hubs are expected to support market growth over the forecast period.

The Germany biopharmaceutical third-party logistics market is anticipated to experience significant growth owing to the country's strong pharmaceutical manufacturing industry and strategic position within the European healthcare supply chain. The increasing production of biologics, specialty pharmaceuticals, and biosimilars is driving demand for specialized warehousing, transportation, and cold chain logistics services. In addition, continued investment in automated logistics facilities and advanced distribution infrastructure is expected to support market expansion.

The UK Biopharmaceutical Third-party Logistics market is expected to grow significantly over the forecast period. The market is supported by a strong biotechnology sector, increasing pharmaceutical exports, and expanding clinical research activities. The growing demand for temperature-controlled logistics, clinical trial distribution, and integrated healthcare supply chain services is encouraging logistics providers to expand service capabilities. Furthermore, investments in digital logistics technologies and healthcare infrastructure are expected to support long-term market growth.

Asia Pacific Biopharmaceutical Third-party Logistics Market Trends

Asia Pacific is expected to grow at a fatest CAGR over the forecast period. Market growth is supported by expanding pharmaceutical manufacturing, increasing biologics production, rising healthcare expenditure, and growing pharmaceutical exports. The increasing outsourcing of logistics operations by pharmaceutical companies and continued investments in cold chain infrastructure are supporting regional market expansion. The development of healthcare logistics networks and increasing regulatory compliance requirements are further contributing to market growth.

The China biopharmaceutical third-party logistics market is anticipated to grow rapidly owing to expanding pharmaceutical manufacturing, increasing biologics commercialization, and rising investments in healthcare infrastructure. The increasing export of pharmaceutical products and growing demand for GDP-compliant cold chain logistics are encouraging logistics providers to expand warehousing and transportation capacity. Moreover, government initiatives supporting pharmaceutical innovation are expected to contribute to market expansion.

The biopharmaceutical third-party logistics market in Japan is expected to witness stable growth supported by a well-established pharmaceutical industry, increasing biologics demand, and advanced healthcare infrastructure. The growing distribution of specialty pharmaceuticals and rising adoption of temperature-controlled logistics solutions are increasing demand for specialized logistics providers. Furthermore, continued investment in digital supply chain management and quality compliant logistics services is expected to support future growth.

The India biopharmaceutical third-party logistics market is expected to witness strong growth over the forecast period. The increasing pharmaceutical production, expanding vaccine manufacturing, and growing exports of biologics and biosimilars are driving demand for specialized logistics services. The continued expansion of temperature-controlled warehousing, healthcare logistics infrastructure, and pharmaceutical distribution networks is expected to support sustained market growth. Furthermore, increasing outsourcing by domestic and multinational pharmaceutical companies is contributing to market expansion.

Latin America Biopharmaceutical Third-party Logistics Market Trends

The Latin America biopharmaceutical third-party logistics industry is experiencing gradual growth supported by increasing pharmaceutical imports, expanding healthcare access, and growing investments in cold chain infrastructure. The rising demand for biologics, vaccines, and specialty pharmaceuticals is encouraging logistics providers to strengthen temperature-controlled transportation and warehousing capabilities. Continued improvements in pharmaceutical distribution networks are expected to support market growth over the forecast period.

The Brazil Biopharmaceutical Third-party Logistics market accounted for the largest share of Latin America in 2025. The country's market growth is supported by increasing pharmaceutical manufacturing, expanding vaccine distribution, and rising biologics demand. The growing requirement for compliant healthcare logistics services and increasing investments in temperature-controlled distribution infrastructure are supporting market expansion. In addition, continued growth in pharmaceutical imports and exports is expected to strengthen demand for specialized third-party logistics services.

Middle East & Africa Biopharmaceutical Third-party Logistics Market Trends

The Middle East and Africa biopharmaceutical third-party logistics industry is expected to experience steady growth supported by increasing pharmaceutical imports, expanding healthcare infrastructure, and growing investment in healthcare logistics. The rising demand for temperature-controlled distribution of biologics, vaccines, and specialty medicines is encouraging the development of specialized logistics capabilities across the region. Continued modernization of pharmaceutical supply chains is expected to support market growth.

The UAE biopharmaceutical third-party logistics market is expected to witness significant growth over the forecast period. The market is supported by the country's strategic location as a regional trade and distribution hub, expanding pharmaceutical imports and exports, and increasing investment in healthcare infrastructure. The development of advanced logistics facilities, free trade zones, and temperature-controlled warehousing is strengthening pharmaceutical distribution capabilities. Furthermore, government initiatives to establish the UAE as a regional life sciences and healthcare logistics hub are expected to support sustained market growth.

Key Biopharmaceutical Third-party Logistics Company Insights

The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in April 2025, DHL Group announced an investment of ~USD 2.3 billion (EUR 2 billion) by 2030 to strengthen its DHL Health Logistics business, expanding GDP-certified pharma hubs, temperature-controlled warehousing, multi-temperature transportation, specialized cooling infrastructure, and digital visibility solutions to support increasing demand from the global biopharmaceutical and advanced therapy sectors.

Key Biopharmaceutical Third-party Logistics Companies

The following key companies have been profiled for this study of the biopharmaceutical third-party logistics market.

• DHL International GmbH

• SF Express

• FedEx

• United Parcel Service of America, Inc.

• Cencora, Inc.

• DB Schenker

• Kuehne and Nagel

• Kerry Logistics Network Limited

• Agility Public Warehousing Company K.S.C.P.

Recent Developments

• In December 2025, Cencora announced investments to enhance its global pharmaceutical third-party logistics services and cold chain capabilities across the U.S. and Europe. The expansion includes the addition of NextPharma Logistics to strengthen its pan-European 3PL network, the establishment of a new 3PL facility in Italy in 2026, and a highly automated 500,000-square-foot 3PL facility in Texas. The investment also expands refrigerated, frozen, ultra-low temperature, and cryogenic storage capacity to support biologics, specialty pharmaceuticals, and cell and gene therapies.

• In March 2025, Kuehne+Nagel partnered with Sanofi to provide fulfillment, handling, and value-added logistics services for healthcare products, including pharmaceuticals in Türkiye. The agreement expands Kuehne+Nagel's healthcare contract logistics capabilities through integrated warehousing, inventory management, and distribution services, supporting efficient regional pharmaceutical supply chains.

Global Biopharmaceutical Third-party Logistics Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical third-party logistics market report based on supply chain, service type, and region:

To learn more about this report, Download Free Sample Report

• Supply Chain Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Cold Chain Logistics

  • Non-cold Chain Logistics

• Service Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • Transportation

    • Air Freight

    • Sea Freight

    • Overland

  • Warehousing and Storage

  • Other Services

• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Qatar

    • Oman

Research Methodology

The biopharmaceutical third-party logistics market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each biopharmaceutical third-party logistics segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations